Conference Reports for NATAP The International Liver Congress EASL - European Association for the Study of the Liver June 21-24 2023 Back Pemvidutide Cuts NAFLD Liver Fat and Weight Through 24 Weeks EASL Congress 2023, June 21-24, Vienna Mark Mascolini Pemvidutide, a novel multiactive agent being developed for obesity and nonalcoholic steatohepatitis (NASH), promoted quick and large drops in liver fat content (LFC), weight, and liver enzymes after 12 and 24 weeks in a 94-person placebo-controlled trial [1]
Such information is not intended to diagnose, prevent, treat, or cure any medical condition, nor should it be relied upon as a substitute for professional medical advice, diagnosis, or treatment
& David S, R
If not, and youre looking for something to help you lose weight, this new FDAapproved drug can be beneficial
Still, the majority of European countries, for example, have imposed very strict utilization controls, generally limiting use to patients with high body mass index
c im ni bt: Cht liu sinh hc t da: Mt n c lm t da ln men, m st da, gip tinh cht thm thu su
